2016 News Releases

Keyword Search
2016 | 2015 | 2014 | 2013 | 2012 | 2011
Date Title
Oct 18, 2016Printer Friendly VersionTakeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma (ISHL)
Oct 10, 2016Printer Friendly VersionCrescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
Sep 16, 2016Printer Friendly VersionTakeda Receives Positive CHMP Opinion for Conditional Approval of NINLAROTM (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple Myeloma
Sep 12, 2016Printer Friendly VersionTakeda Supports Global Expansion of the American Cancer Society’s Relay For Life (RFL)
Aug 31, 2016Printer Friendly VersionTakeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma
Aug 08, 2016Printer Friendly VersionPatients with Multiple Myeloma and Their Supporters Are Hiking Peru’s Inca Trail To Machu Picchu to Bolster Awareness and Drive Fundraising for Cancer Research
Aug 08, 2016Printer Friendly VersionTakeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma
Aug 01, 2016Printer Friendly VersionTakeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Jul 18, 2016Printer Friendly VersionSeattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
Jul 06, 2016Printer Friendly VersionTakeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Jul 04, 2016Printer Friendly VersionTakeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
Jun 16, 2016Printer Friendly VersionTakeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health Informatics
May 27, 2016Printer Friendly VersionTakeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
May 27, 2016Printer Friendly VersionTakeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in Relapsed/Refractory Multiple Myeloma
Apr 27, 2016Printer Friendly VersionPhase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine
Feb 26, 2016Printer Friendly VersionJapanese MHLW Grants Orphan Drug Designation in Japan to Takeda's Oral Proteasome Inhibitor Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2016Printer Friendly VersionMersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522
Jan 22, 2016Printer Friendly VersionEuropean Commission Approves Label Variation for ADCETRIS® (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL)